New Insight: A Recap of ASRS 2023

News
Podcast

In this episode, host Veeral Sheth, MD, and producer Connor Iapoce discuss 5 presentations from ASRS 2023. The discussion centered around new data on geographic atrophy therapies, novel agents for DME, and the feasibility of home OCT.

Episode Highlights

0:23 - Introduction

1:49 - Pegcetacoplan vs. Avacincaptad Pegol

9:44 - Long-Term Efficacy of Pegcetacoplan

13:12 - Concerns with Pegcetacoplan

14:41 - Feasibility of Home OCT

19:05 - UBX1325 for DME

23:21 - Results from Phase 3 GLIMMER and GLEAM

26:11 - Conclusion

Earlier this month, the American Society of Retina Specialists (ASRS) held its 41st Annual Meeting in Seattle, Washington, serving as a focal point for the ever-changing retina community.

Central themes for the 2023 meeting included the exploration of the newly approved geographic atrophy (GA) drug class, novel therapies in the pipeline for retinal diseases, and technological advancements in the field.

The impact of these presentations was discussed in the latest episode of New Insight with Veeral Sheth, MD. Host Veeral Sheth, MD, and show producer Connor Iapoce, zeroed in on 5 exciting presentations from ASRS 2023, breaking down the findings and describing the potential implications on clinical practice.

The 5 presentations included:

  • "Pegcetacoplan (SYFOVRE) vs. Avacincaptad Pegol (IZERVAY) in Patients with Geographic Atrophy: An Anchored Matching-Adjusted Indirect Comparison of the Phase 3 Trials"
  • "Long-Term Efficacy of Pegcetacoplan in Patients with Geographic Atrophy"
  • "Daily Imaging with Home Optical Coherence Tomography Among Treatment-Naive Neovascular Age-Related Macular Degeneration Participants"
  • "48-Week End of Study Results from BEHOLD Phase 2 Study of UBX1325 in Patients with DME"
  • "Tacrocimab Tedromer (KSI-301) Anti-VEGF Antibody Biopolymer Conjugate for DME: First-Time Efficacy, Durability, and Safety Results of the GLEAM and GLIMMER Phase 3 Studies"

Every episode of New Insight is available on HCPLive.com and be sure to subscribe to our channel on Spotify, Apple Podcasts, and YouTube. Please direct any podcast-related inquiries to show producer Connor Iapoce at ciapoce@mjhlifesciences.com.

Keep an eye out for more from New Insight!

Recent Videos
1 KOL is featured in this Insights series.
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
Discussing Post-Hoc Data on Ruxolitinib for Nonsegmental Vitiligo, with David Rosmarin, MD
A panel of 3 experts on dry eye
1 KOL is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.